Centessa

BOSTON and LONDON, July 10, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage…
Read More...

- Registrational studies planned to start in 4Q 2022 - - Two-year data from Phase 2a Open Label Extension study…
Read More...

BOSTON and LONDON, June 05, 2022 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage…
Read More...

BOSTON and LONDON, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA) (the “Company”),…
Read More...

~ El trabajo de investigación se centrará en moléculas pequeñas con perfiles clínicos diferenciados para aprovechar el…
Read More...

~ 88 % de reducción en la mediana de la tasa anualizada de hemorragia (TAH) para todas las hemorragias y 94 % de…
Read More...